Form 4 for GNLX GENELUX Corp
Accepted 2023-10-11 00:00:00 ET · period of report 2023-10-10 · accession 0001209191-23-052621 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-11 | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| DM | 2023-10-11 | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $22.01 | -5,200 | 106.5K | -5% | -$114.5K |
| D | 2023-10-11 | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $0.00 | -5,200 | 212.9K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-10 | M | A | 5,200 | $6.00 | 111,335 | D | — | — | |
| 2 | Common | Common Stock | 2023-10-10 | S | D | 400 | $22.91 | 106,135 | D | — | — | (F3) The weighted average sale price for the transaction reported was $22.906, and the range of prices were between $22.82 and $22.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2023-10-10 | S | D | 4,800 | $21.94 | 106,535 | D | — | — | (F2) The weighted average sale price for the transaction reported was $21.9374, and the range of prices were between $21.54 and $22.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Derivative | Stock Option (right to buy) | 2023-10-10 | M | D | 5,200 | $0.00 | 212,853 | D | $6.00 · — to 2029-09-20 | 5,200 Common Stock | (F4) Immediately exercisable. |